Curavit has joined the Decentralized Trials & Research Alliance, an industry-backed non-profit organization focused on the promotion of remote studies.
Membership of the group will see Curavit take part in the development of the fast growing the decentralized clinical trials market according to co-founder, president and chief commercial officer, Dave Hanaman.
“DTRA provides a broader platform for Curavit to discuss the innovations and research improvements that we are driving for our clients. Curavit will also have the benefit of collaborating with other innovators to solve new or emerging challenges in a way that is meaningful for the entire industry.”
Demand for decentralized trials has increased significantly in recent years – particularly since the pandemic – Hanaman told Clinical insider and predicted demand would continue.
“Curavit sees demand for DCTs daily in the form of customer feedback. Clients are developing long-term plans to leverage decentralized components in most of their trials. COVID-19 changed the industry’s approach, impacting everything from long-range planning to execution and it doesn’t seem like we are going back to traditional methods.”
He added, “Today, most trial designs have at least on decentralized component included and every large pharmaceutical company Curavit has spoken to over the last year has established a DCT group or team – often referenced as innovation team, trial optimization group, digital team or other similar nomenclature denoting DCTs.”
Curavit was established in 2020 in a bid to tap this growing section of the market. Last month the CRO expanded its sales team in a bid to broaden its service.
Hanaman said, “Curavit is a new company and establishing its sales force from scratch, so we need team members to support the demand. Prior, just Curavit founders have been managing client inquiries and working with clients to ensure long-term satisfaction and responsiveness.
“With our growth, that is not sustainable, as the Curavit leadership also need to devote time to helping to develop unique therapeutic-area-specific solutions for our clients.”
Image: Stock Photo Secrets